Page 2 - Johnson And Johnson

J&J wins pause of baby powder trials, must face new suits, says judge

US Bankruptcy Judge Michael Kaplan said Thursday the company won't have to go to trial over any talc lawsuits for at least 60 days, but new lawsuits can be filed

J&J May Need to Defend Baby Powder Cancer Suits After 19-Month Pause

The company says it has a deal backed by as many as 80,000 claimants, which should be enough to meet a key legal threshold to push a settlement worth $8.9 billion through bankruptcy

Johnson&Johnson sales in US rise 10%, health care giant raises dividend

Johnson & Johnson beat first-quarter expectations, as growth in the health care giant's home market helped counter another revenue hit overseas from a strong dollar. The health care giant booked a USD 68 million loss on a one-time charge in the quarter, and revenue grew more than 5 per cent to USD 24.75 billion, which was better than anticipated. Adjusted earnings totalled USD 2.68 per share, topping Wall Street projections for per-share earnings of USD 2.50, according to a survey by FactSet. Johnson & Johnson sells prescription drugs and medical devices. It is splitting off its consumer health business, which includes well-known products like BandAids. The company expects to complete the separation this year. Sales in the US grew nearly 10 per cent to USD 12.52 billion in the quarter, while international sales climbed nearly 2 per cent. A strong US dollar can affect sales for companies that do a lot of international business. They have to convert those sales into dollars when

Wall St up as Goldman results keep optimism alive, rising yields cap gains

The benchmark 10-year Treasury note reversed early declines to rise for the fourth straight day, while big technology and growth names like Apple Inc, Amazon.com and Nvidia Corp cut back gains

Q3 results: Johnson & Johnson beats estimates on demand for cancer drug

The company said it expects some impact of inflation to ease next year but higher costs of inventory manufactured in 2022 could weigh on 2023 profit

Maharashtra FDA axe Johnson & Johnson's baby powder manufacturing license

Maharashtra's Food and Drugs Administration (FDA) on Friday cancelled the baby powder manufacturing licence of Johnson & Johnson Pvt Ltd "in the interest of public health at large". In a release, the state government agency said the company's product, Johnson's Baby Powder, may affect the skin of newborn babies. Samples of the powder for babies did not conform to standard pH value during a laboratory test, the regulator said. The release said the action was taken after Kolkata-based Central Drugs Laboratory's conclusive report that concludes "the sample does not conform to IS 5339:2004 with respect to the test for pH. According to the release, FDA had drawn samples of Johnson's Baby Powder from Pune and Nashik for quality check purposes. The government analyst had declared the samples as "not of the standard quality" as they do not comply with IS 5339:2004 specification for skin powder for infants in the test pH, it said. Thereafter, FDA issued a show-cause notice to ...

Explained: What is the controversy around J&J's talc-based baby powder?

Johnson and Johnson (J&J) has been facing several thousand lawsuits from women who claim that they developed ovarian cancer after using the product

Johnson and Johnson: Why talc-based powder will stop their sales in 2023?

After 38,000 serious allegations, Johnson and Johnson's talc-based baby powder will stop international sales from 2023. The product has already been discontinued in the US and Canada

Johnson & Johnson offloads talc liabilities into newly created subsidiary

(Reuters) -Johnson & Johnson on Thursday put into bankruptcy tens of thousands of legal claims alleging its Baby Powder and other talc-based products caused cancer, offloading the potential liabilities into a newly created subsidiary.

Expert panel allows adolescent trials of J&J vaccine with riders

SEC asks J&J to monitor adverse events closely for next three months

J&J's single-dose Covid vaccine gets approval for emergency use in India

Now India has 5 EUA vaccines. This will further boost our nation's collective fight against Covid, says Union Health Minister Mansukh Mandaviya

Discussing indemnity, other issues with foreign Covid vaccine makers: Govt

A team of central government officials is in continuous dialogue with foreign Covid vaccine manufactures like Pfizer, Moderna and Johnson and Johnson to discuss and address various issues

World Coronavirus Dispatch: Rare nerve complication with J&J vaccine

FDA adds warning on Johnson & Johnson vaccine, lockdown extensions looms in Sydney and other pandemic-related news across the globe

India in talks with Johnson & Johnson for single-dose Covid-19 vaccine

New Delhi [India], July 2 (ANI): NITI Aayog member (Health) Dr VK Paul on Friday confirmed that India is in talks with US pharma giant Johnson & Johnson for their single-dose COVID-19 vaccine named Janssen.Speaking exclusively to ANI, Dr Paul said, "We are in talks with Johnson & Johnson regarding their single-dose vaccine."He said that "as per the plan, this vaccine will also be produced in Hyderabad's Bio E."Johnson & Johnson said late on Thursday that its COVID-19 vaccine showed strong promise against the Delta variant and other emerging strains and also provided durable protection against the infection more broadly. The healthcare company in a statement said that its vaccine was 85 per cent effective and could also help prevent hospitalisation and death.Presently, in India Delta plus has been reported in 12 states. This variant is a sub-lineage of delta variant and has been declared as 'Variant of Concern' by the government.According to Dr Paul, India reported 56

US extends expiration dates for Johnson & Johnson Covid vaccine by 6 weeks

Johnson & Johnson said Thursday that U.S. regulators extended the expiration date on millions of doses of its COVID-19 vaccine by six weeks. The company said a Food and Drug Administration review concluded the shots remain safe and effective for at least 4 1/2 months. In February, the FDA originally authorised J&J's vaccine for up to three months when stored at normal refrigeration levels. Thursday's announcement comes after state officials warned that many doses in storage would expire before the end of the month. Vaccine expiration dates are based on information from drugmakers on how long the shots stay at the right strength. J&J said the FDA added six weeks based on data from ongoing studies assessing the vaccine's stability. The FDA has been reviewing expiration dates on all three U.S. authorised vaccines as companies have continued to test batches in the months since the shots first rolled out. The vaccines from Pfizer and Moderna, authorized in December, have a ...

Belgium suspends Johnson & Johnson vaccine for under 41s after death

Belgium on Wednesday suspended the use of the Johnson & Johnson COVID-19 vaccine for people under age 41 following the death of a person who had received the shot. The government said in a statement it was asking for urgent advice from the European Medicines Agency, the European Union's drug regulator, before it would consider lifting the suspension. It added that the impact on the national vaccination drive would be very limited. Belgium was using the Johnson & Johnson vaccine for elderly with reduced mobility and the homeless since it only takes one shot to be protected. Those shots will be continued. It said it took the action after a single case where there was serious side effects after administering the Janssen vaccine, using the local name for the Johnson & Johnson shot. It said a woman was vaccinated through her foreign employer outside the Belgian system and had died in Belgium last week after developing serious thrombosis and reduced blood platelets. It didn't ...

J&J working with Telangana-based company to manufacture Covid vaccine

US pharmaceutical giant Johnson and Johnson has joined hands with Biological E Limited (Telangana-based pharma company) for the manufacturing of the COVID-19 vaccine, as per an official statement on Tuesday.The company's vaccine named, Janssen COVID-19 vaccine is currently approved for use in the United States, the European Union and other nations including Thailand and South Africa."Johnson & Johnson is working with Biological E. Limited on the manufacturing of the Johnson COVID-19 vaccine. We believe Biological E. will be an important part of our global COVID-19 vaccine supply network, where multiple manufacturing sites are involved in the production of our vaccine across different facilities, sometimes in different countries and continents, before the vaccine can be distributed", read an official statement by Johnson and Johnson."We are working around the clock to develop and broadly activate our manufacturing capabilities to supply our COVID-19 vaccine worldwide and we ...

US looking at joint production of J&J's Covid-19 vaccine in India

US is looking at joint production of Johnson and Johnson's Covid-19 vaccine in India and ways to help manufacturers like the Serum Institute of India to boost production

EU agency links J&J vaccine shot to rare clots, says odds favour use

The European Union's drug regulatory agency said Tuesday that it found a possible link between Johnson & Johnson's COVID-19 vaccine and extremely rare blood clots and that a warning should be added to the label. But experts at the agency reiterated that the vaccine's benefits outweigh the risks. The European Medicines Agency made those determinations after a very small number of blood clot cases in people who had gotten the vaccine were reported in the United States. The agency said a warning about the blood clots should be added to labels for the Johnson & Johnson's vaccine and that these rare blood disorders should be considered very rare side effects of the vaccine. The EMA also recommended a label change for the AstraZeneca COVID-19 vaccine after finding a link between it and rare blood clots. In both cases, the agency said the benefits of being immunized against COVID-19 still outweighed the very small risks of recipients developing the unusual clots. Last week, Johnson ..

EU not to renew AstraZeneca, J&J Covid-19 vaccine contracts on expiry

A spokesman for the EU Commission said it was keeping all options open to be prepared for the next stages of the pandemic, for 2022 and beyond